|
|
|
|
|
|
|
|
|
|
CONCLUSIONS:
MSI prevalence is negligible in sporadic, resected PDAC. Differently, the prevalence of pancreatic cancer is 2.5% in LS patients, and cancers other than PDAC may be encountered in this setting. Surveillance for pancreatic cancer should be advised in LS mutation carriers at referral centers.
http://www.ncbi.nlm.nih.gov/m/pubmed/23029359/?i=1&from=lynch%20syndrome
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.